Esther Lu

Medicine & Life Sciences

1. 130-nm albumin-bound paclitaxel 49%
2. Adenocarcinoma 56%
3. Albumin-Bound Paclitaxel 25%
4. Allogeneic Cells 26%
5. Alzheimer Disease 43%
6. Arnold-Chiari Malformation 23%
7. Biomarkers 34%
8. Body Mass Index 23%
9. Breast Neoplasms 39%
10. Cancer Survivors 75%
11. Cetuximab 35%
12. Clinical Trials 31%
13. Comorbidity 23%
14. Confidence Intervals 40%
15. Costs and Cost Analysis 30%
16. Decision Support Techniques 28%
17. Diet 35%
18. Drug Therapy 40%
19. Endometrial Neoplasms 24%
20. Four-Dimensional Computed Tomography 26%
21. gemcitabine 33%
22. Health 46%
23. Health Insurance 31%
24. Implementation Science 24%
25. Lung 39%
26. Lung Neoplasms 26%
27. Lymphoma, Large B-Cell, Diffuse 27%
28. Mortality 55%
29. Neoadjuvant Therapy 24%
30. Neoplasms 100%
31. Neuroendocrine Tumors 25%
32. Non-Small Cell Lung Carcinoma 28%
33. Odds Ratio 29%
34. Overweight 36%
35. Pancreatic Neoplasms 59%
36. Pancreaticoduodenectomy 53%
37. Progression-Free Survival 34%
38. Prostatic Neoplasms 39%
39. Quality of Life 26%
40. Radiosurgery 35%
41. Radiotherapy 40%
42. Randomized Controlled Trials 49%
43. Recurrence 54%
44. Squamous Cell Carcinoma of Head and Neck 39%
45. Survival 91%
46. Therapeutics 31%
47. Tissue Donors 33%
48. Tomography 24%
49. Transplants 39%
50. Weight Loss 60%